A sclerostin super-producer cell line derived from the human cell line SaOS-2: A new tool for the study of the molecular mechanisms driving sclerostin expression

Calcified Tissue International

Volumn 95, Issue 2, 2014, Pages 194-199

  Pérez Campo, Flor M ^a   Sañudo, Carolina ^a   Delgado Calle, Jesús ^a   Arozamena, Jana ^a   Zarrabeitia, María T ^a   Riancho, José A ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Bone homeostasis; Osteoporosis; SaOS 2 human cell line; Sclerostin

Indexed keywords

PARATHYROID HORMONE; SCLEROSTIN; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, HUMAN; TRANSCRIPTOME;

ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA DETERMINATION; DNA METHYLATION; FREEZE THAWING; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SAOS 2 CELL LINE; BIOSYNTHESIS; BONE DEVELOPMENT; DNA MICROARRAY; GENETIC MARKER; METABOLISM; OSTEOSARCOMA; PHYSIOLOGY; TUMOR CELL LINE;

BONE MORPHOGENETIC PROTEINS; CELL LINE, TUMOR; GENETIC MARKERS; HUMANS; IMMUNOBLOTTING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOGENESIS; OSTEOSARCOMA; TRANSCRIPTOME;

EID: 84905562947     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-014-9880-5     Document Type: Article

References (26)

1. Raggatt LJ, Partridge NC (2010) Cellular and molecular mechanisms of bone remodeling. J Biol Chem 285:25103-25108
2. Vaananen HK, Zhao H, Mulari M, Halleen JM (2000) The cell biology of osteoclast function. J Cell Sci 113(Pt 3):377-381 (Pubitemid 30116644)
3. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883-19887 (Pubitemid 41379516)
4. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578-588
5. McColm J, Hu L, Womack T, Tang CC, Chiang AY (2014) Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res 29(4):935-943.
6. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537-543 (Pubitemid 32184286)
7. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68:577-589 (Pubitemid 32202753)
8. Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, Thesleff I, Itoh N (2003) Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 278:24113-24117 (Pubitemid 36830246)
9. Delgado-Calle J, Arozamena J, Garcia-Renedo R, Garcia-Ibarbia C, Pascual-Carra MA, Gonzalez-Macias J, Riancho JA (2011) Osteocyte deficiency in hip fractures. Calcif Tissue Int 89:327-334
10. Bonewald LF (2011) The amazing osteocyte. J Bone Miner Res 26:229-238
11. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842-1844 (Pubitemid 41598769)
12. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267-6276 (Pubitemid 37522584)
13. Jager A, Gotz W, Lossdorfer S, Rath-Deschner B (2010) Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro. J Periodontal Res 45:246-254
14. Pockwinse SM, Wilming LG, Conlon DM, Stein GS, Lian JB (1992) Expression of cell growth and bone specific genes at single cell resolution during development of bone tissue-like organization in primary osteoblast cultures. J Cell Biochem 49:310-323
15. Delgado-Calle J, Sanudo C, Bolado A, Fernandez AF, Arozamena J, Pascual-Carra MA, Rodriguez-Rey JC, Fraga MF, Bonewald L, Riancho JA (2012) DNA methylation contributes to the regulation of sclerostin expression in human osteocytes. J Bone Miner Res 27:926-937
16. Delgado-Calle J, Arozamena J, Perez-Lopez J, Bolado-Carrancio A, Sanudo C, Agudo G, de la Vega R, Alonso MA, Rodriguez-Rey JC, Riancho JA (2013) Role of BMPs in the regulation of sclerostin as revealed by an epigenetic modifier of human bone cells. Mol Cell Endocrinol 369:27-34
17. Delgado-Calle J, Riancho JA, Klein-Nulend J (2014) Nitric oxide is Involved in the down-regulation of SOST expression induced by mechanical loading. Calcif Tissue Int 94:414-422
18. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM (2005) Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Gen Res 15:928-935 (Pubitemid 40994212)
19. Keller H, Kneissel M (2005) SOST is a target gene for PTH in bone. Bone 37:148-158 (Pubitemid 40962421)
20. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 283:5866-5875
21. Sevetson B, Taylor S, Pan Y (2004) Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST). J Biol Chem 279:13849-13858 (Pubitemid 38468917)
22. Yoshida CA, Furuichi T, Fujita T, Fukuyama R, Kanatani N, Kobayashi S, Satake M, Takada K, Komori T (2002) Core-binding factor beta interacts with Runx2 and is required for skeletal development. Nat Genet 32:633-638 (Pubitemid 35435176)
23. Kundu M, Javed A, Jeon JP, Horner A, Shum L, Eckhaus M, Muenke M, Lian JB, Yang Y, Nuckolls GH, Stein GS, Liu PP (2002) Cbfbeta interacts with Runx2 and has a critical role in bone development. Nat Genet 32:639-644 (Pubitemid 35435177)
24. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Lowik CW (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805-814 (Pubitemid 38375200)
25. Galea GL, Sunters A, Meakin LB, Zaman G, Sugiyama T, Lanyon LE, Price JS (2011) Sost down-regulation by mechanical strain in human osteoblastic cells involves PGE2 signaling via EP4. FEBS Lett 585:2450-2454
26. Yu L, van der Valk M, Cao J, Han CY, Juan T, Bass MB, Deshpande C, Damore MA, Stanton R, Babij P (2011) Sclerostin expression is induced by BMPs in human Saos-2 osteosarcoma cells but not via direct effects on the sclerostin gene promoter or ECR5 element. Bone 49:1131-1140